TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2019

Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy.

Paul Nghiem et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.